Omron Healthcare Co, Ltd announced additional investment into AliveCor by its Japanese parent company, Omron Corporation, as part of $65 million series E funding for the leader in AI-based personal electrocardiogram (ECG) technology. Omron led this round of investment, reinforcing the cross-company collaboration that began in 2017. The companies continue to build on their global alliance to accelerate development of solutions for cardiovascular disease management and remote patient monitoring utilising ECG technology.

"Omron is committed to developing life-saving cardiovascular health technologies in pursuit of our 'Going for Zero' vision to eliminate heart attacks and strokes. That is why we seek like-minded partners, like AliveCor, to advance our initiatives and work together to save lives," said Isao Ogino, President and CEO, Omron Healthcare.

"Our alliance with AliveCor will help enhance our current technology portfolio and provide hypertensive patients and healthcare professionals with data that can save lives--a complete picture of patients' cardiovascular health that can be achieved with personal remote monitoring technology used at home,” said Ogino.

Omron's expanded investment into AliveCor builds upon the companies' ongoing collaboration. Omron expanded its blood pressure monitor portfolio with the launch of ‘Complete’ (TM) the first blood pressure monitor with ECG capability in a single device and the first FDA-cleared technology developed in collaboration with AliveCor in 2019. Currently available in the US at OmronHealthcare.com and participating retailers, expanded distribution of Complete (TM) is expected in other regions globally during the company's fourth quarter.